IgA Vasculitis: Influence of CD40, BLK and BANK1 Gene Polymorphisms.
Joao Carlos Batista LizFernanda GenreVerónica Pulito-CuetoSara Remuzgo MartinezDiana Prieto-PeñaAna MárquezNorberto Ortego-CentenoMaría Teresa LeonardoAna PeñalbaFrancisco Javier NarváezLuis Martín-PenagosLara Belmar-VegaCristina Gómez-FernándezJosé A Miranda-FilloyLuis Caminal-MonteroPaz ColladoDiego De ÁrgilaPatricia Quiroga-ColinaEsther F Vicente-RabanedaAna Triguero-MartínezEsteban RubioManuel León LuqueJuan María Blanco-MadrigalEva Galíndez-AgirregoikoaJavier MartínOreste GualilloRicardo BlancoSantos CastañedaMiguel Angel González-GayRaquel Lopez-MejiasPublished in: Journal of clinical medicine (2022)
CD40, BLK and BANK1 genes involved in the development and signaling of B-cells are identified as susceptibility loci for numerous inflammatory diseases. Accordingly, we assessed the potential influence of CD40, BLK and BANK1 on the pathogenesis of immunoglobulin-A vasculitis (IgAV), predominantly a B-lymphocyte inflammatory condition. Three genetic variants within CD40 (rs1883832, rs1535045, rs4813003) and BLK (rs2254546, rs2736340, rs2618476) as well as two BANK1 polymorphisms (rs10516487, rs3733197), previously associated with inflammatory diseases, were genotyped in 382 Caucasian patients with IgAV and 955 sex- and ethnically matched healthy controls. No statistically significant differences were observed in the genotype and allele frequencies of CD40, BLK and BANK1 when IgAV patients and healthy controls were compared. Similar results were found when CD40, BLK and BANK1 genotypes or alleles frequencies were compared between patients with IgAV stratified according to the age at disease onset or to the presence/absence of gastrointestinal or renal manifestations. Moreover, no CD40, BLK and BANK1 haplotype differences were disclosed between patients with IgAV and healthy controls and between patients with IgAV stratified according to the clinical characteristics mentioned above. Our findings indicate that CD40, BLK and BANK1 do not contribute to the genetic background of IgAV.